M
512.39
-6.35 (-1.22%)
| Penutupan Terdahulu | 518.74 |
| Buka | 518.00 |
| Jumlah Dagangan | 200,289 |
| Purata Dagangan (3B) | 358,453 |
| Modal Pasaran | 11,754,210,304 |
| Harga / Pendapatan (P/E Ke hadapan) | 666.67 |
| Harga / Jualan (P/S) | 12.14 |
| Harga / Buku (P/B) | 19.74 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 May 2026 |
| Margin Keuntungan | -123.38% |
| Margin Operasi (TTM) | -57.79% |
| EPS Cair (TTM) | -17.83 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 16.85% |
| Nisbah Semasa (MRQ) | 5.91 |
| Aliran Tunai Operasi (OCF TTM) | -395.31 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -274.11 M |
| Pulangan Atas Aset (ROA TTM) | -25.56% |
| Pulangan Atas Ekuiti (ROE TTM) | -50.16% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Madrigal Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
2.1
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | 2.5 |
| Purata | 2.13 |
|
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 7.73% |
| % Dimiliki oleh Institusi | 108.28% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Paulson & Co. Inc. | 31 Dec 2025 | 1,707,522 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 964.00 (Barclays, 88.14%) | Beli |
| Median | 746.50 (45.69%) | |
| Rendah | 529.00 (B of A Securities, 3.24%) | Pegang |
| Purata | 746.50 (45.69%) | |
| Jumlah | 1 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 465.78 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| B of A Securities | 20 Feb 2026 | 529.00 (3.24%) | Pegang | 435.01 |
| Barclays | 28 Jan 2026 | 964.00 (88.14%) | Beli | 496.54 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 02 Feb 2026 | Pengumuman | Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |